Connect with us

Hi, what are you looking for?

Oracle of  Omaha Says – Investing and Stock NewsOracle of  Omaha Says – Investing and Stock News

Editor's Pick

Eli Lilly stock price forecast ahead of obesity drug approval

Eli Lilly & Co (NYSE: LLY) has rallied over the past three months but a Bank of America analyst says it’s not out of room to run just yet.

Lilly stock should be worth $500

Geoff Meacham raised his price objective on the pharmaceutical behemoth in a research note this morning to $500 – up another 20% from here.

He expects the Eli Lilly stock to benefit as demand escalates for its obesity drug (Tirzepatide) that helped patients lose 16% of their body weight in a recent clinical study.

Consumer/social media trends bolster our confidence in Tirzepatide’s commercial opportunity, as patients seem very interested in anti-obesity medications, regardless of the administrative modality.

Eli Lilly now expects FDA approval for its weight loss drug by the end of this year.   

Tirzepatide’s demand will increase

Geoff Meacham estimates demand for Lilly’s obesity drug to increase by 40% over the next seven years.

Mounjaro is not eligible for reimbursement under health insurance for now. But the BofA analyst is convinced that will change moving forward. All in all, he expects Tirzepatide to be a $20 billion drug by 2030.

In April, Eli Lilly & Co raised its outlook for the full financial year related partially to the weakening U.S. dollar. It now forecasts revenue to fall between $31.2 billion and $31.7 billion in fiscal 2023.

Earlier this month, famed investor Jim Cramer also dubbed the company’s Alzheimer’s drug a holy grail as Invezz reported here.

The post Eli Lilly stock price forecast ahead of obesity drug approval appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Everynet, one of the world’s largest network operators for national LoRaWAN® networks, announces it is working with Amazon Web Services (AWS) to offer long-range...


    As more candidates throw their hats into the 2024 Presidential ring, I’d like to offer a proposal that should have immediate bipartisan support: stop...

    Editor's Pick

    The Internet of Things (IoT) is changing the way we interact with technology, and it has the potential to revolutionize the way we manage...

    Editor's Pick

    Semtech Corporation and esteemed engineering design services firm, Connected Development, today announced the launch of the new XCVR Development Board and Reference Design integrating...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023